MISSOULA, Mont., July 24,
2024 /PRNewswire/ -- Inimmune, a clinical stage
biotech company focused on the development of novel
immunotherapies, vaccines, and vaccine adjuvants announced today
the dosing of the first patient in its Phase 1 single ascending
dose study of INI-4001 in patients with advanced solid tumors.
This is an open-label, multiple-ascending dose, two-part dose
ranging and cohort expansion study of INI-4001 in patients with
advanced solid tumors. This first-in-human trial of INI-4001,
Inimmune's proprietary TLR7/8 agonist in a nanoparticle delivery
system, will consist of two parts. In Phase 1a, single dose
escalation cohorts receiving monotherapy INI-4001 will determine
PK, safety, and tolerability. This is followed by Phase
1b where patients who have progressed
or have stable disease after 3 cycles of INI-4001 will be allowed
to receive concurrent administration of an anti-PD-1 or anti-PD-L1
immunotherapy plus INI-4001.
In pre-clinical studies, INI-4001 was efficacious both as a
monotherapy and in combination with anti-PD-1 checkpoint therapy in
syngeneic murine tumors (LLC, MC38 and B16F10). Additionally,
INI-4001 has been shown to induce production of the cytokine IFNα
and activation of antigen presenting cells, leading to downstream T
cell activation in vivo. INI-4001 may prove to be an ideal
combination agent with checkpoint inhibitors given that a minority
of patients currently benefit from checkpoint inhibitor
monotherapy.
Inimmune's CEO, Alan Joslyn, said
"We are very excited that INI-4001 clinical trials have commenced,
as this marks an important milestone for our company and oncology
patients. INI-4001 either as monotherapy or in combination with
checkpoint therapy can potentially provide physicians a new
therapeutic option in their treatment toolbox."
Inimmune's trial of INI-4001 is being conducted in Australia and is expected to be complete by
the end of 2025. Additional information can be found at
clinicaltrials.gov (NCT06302426).
About Inimmune:
Inimmune Corp. (Missoula, MT) is a privately held clinical
stage biotechnology company focused on the discovery and
development of novel immunotherapies, vaccines, and vaccine
adjuvants. Inimmune is harnessing the human immune system to create
safe and effective treatments for allergy, infectious disease,
autoimmunity and cancer. Their laboratories and offices
are housed in the Montana Technology Enterprise Center (MonTEC)
in Missoula.
For more information on Inimmune's research and development
of novel vaccine adjuvants and delivery systems, please visit
www.inimmune.com.
Contact:
Media Relations
Inimmune Corporation
Phone: (406)-541-5913
Email: info@inimmune.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inimmune-announces-first-cancer-patient-dosed-in-phase-1-clinical-study-using-the-immunotherapeutic-ini-4001-a-novel-tlr78-agonist-302204890.html
SOURCE Inimmune Corporation